US · Healthcare · Biotechnology
EPS came in at -1.84 against a street estimate of -1.98 — a beat of 7.1%.
Analysts rate NextCure Inc a buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $20.00.
| Fund | Stake |
|---|---|
| Adage Capital Partners Gp LLC | 6.06% |
| Affinity Asset Advisors, LLC | 5.28% |
| Ikarian Capital, LLC | 5.21% |
| Sofinnova Ventures | 4.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 3.85% |
| Vanguard Capital Management, LLC | 3.51% |
| Pfizer Inc | 3.35% |
| Awm Investment Company Inc | 2.56% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for NextCure Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.